Januvia Type II Diabetes Drug
Januvia, Merck & Company’s brand name for sitagliptin, is a once daily anti-diabetic medication for patients with type 2 diabetes. Approved by the FDA in 2006, Januvia is used to control blood sugar levels and has been prescribed to millions of patients in 80 countries.
Januvia inhibits the enzyme dipeptidyl peptidase-4 (DPP-4) which extends the life of the hormones that stimulate insulin production. This action causes the body to absorb more sugar, thus decreasing high levels of sugar in the blood.
However, Januvia has also been shown to cause negative effects on the body. Studies now suggest that Januvia and similar diabetes medications may be associated with increased rates of pancreatitis, pancreatic cancer, and thyroid cancer among users.
In 2009, the FDA warned of increased pancreatitis risks linked to Januvia. This came after the agency received nearly 90 reports of Januvia users developing pancreatitis in just over two years. Because of this, Merck was required to add label warnings, but the drug was allowed to remain on the market.
Then, in 2011, a study from the University of California at Los Angeles uncovered additional adverse effects from using Januvia: a 600 percent increased risk of pancreatitis, a 270 percent increased risk of pancreatic cancer, and a 148 percent increased risk of thyroid cancer.
Unfortunately for consumers, Merck knew as early as 2008 about the risks and did not warn its users. Therefore, Merck is liable for damages. Lawyers are now helping patients who were affected to file lawsuits.
If you or a family member were diagnosed with thyroid cancer or pancreatic cancer following Januvia use, a lawyer can discuss your case to let you know what help is available. Contact us today for more information.